Literature DB >> 25426811

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?.

Jonathan Underwood, Kevin R Robertson, Alan Winston.   

Abstract

Whilst effective antiretroviral therapy is protective against the more severe forms of HIV-associated brain disease, there remains a large burden of clinically symptomatic cognitive impairment in the modern era. Although several potential pathogenic mechanisms have been proposed, the underlying pathology remains elusive. In this review, we summarize the evidence describing neuronal toxicity of antiretroviral agents themselves in both preclinical and clinical situations, as well as the potential pathological mechanisms underlying this toxicity. We also consider the implications for future practice and clinical research in which case determining optimal antiretroviral combinations that effectively suppress HIV replication whilst minimizing neurotoxic effects on the central nervous system may become paramount.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25426811     DOI: 10.1097/QAD.0000000000000538

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  57 in total

1.  Empiric neurocognitive performance profile discovery and interpretation in HIV infection.

Authors:  Daniela Gomez; Christopher Power; M John Gill; Noshin Koenig; Roberto Vega; Esther Fujiwara
Journal:  J Neurovirol       Date:  2018-12-05       Impact factor: 2.643

2.  Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.

Authors:  Hamza Coban; Kevin Robertson; Marlene Smurzynski; Supriya Krishnan; Kunling Wu; Ronald J Bosch; Ann C Collier; Ronald J Ellis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

3.  Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Gert U van Zyl; Lubbe Wiesner; Saye Khoo; John A Joska; David W Haas; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

4.  Structural brain changes in perinatally HIV-infected young adolescents in South Africa.

Authors:  Jacqueline Hoare; Jean-Paul Fouche; Nicole Phillips; John A Joska; Landon Myer; Heather J Zar; Dan J Stein
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

5.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

6.  No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Authors:  Edwina J Wright; Birgit Grund; Kevin R Robertson; Lucette Cysique; Bruce J Brew; Gary L Collins; Mollie Poehlman-Roediger; Michael J Vjecha; Augusto César Penalva de Oliveira; Barbara Standridge; Cate Carey; Anchalee Avihingsanon; Eric Florence; Jens D Lundgren; Alejandro Arenas-Pinto; Nicolas J Mueller; Alan Winston; Moses S Nsubuga; Luxshimi Lal; Richard W Price
Journal:  AIDS       Date:  2018-05-15       Impact factor: 4.177

Review 7.  Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls.

Authors:  Dietrich Haubenberger; David B Clifford
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 8.  CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.

Authors:  Andrea Calcagno; Ambra Barco; Mattia Trunfio; Stefano Bonora
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

Review 9.  Heterogeneity of Neuropsychological Impairment in HIV Infection: Contributions from Mild Cognitive Impairment.

Authors:  Kathryn N Devlin; Tania Giovannetti
Journal:  Neuropsychol Rev       Date:  2017-05-24       Impact factor: 7.444

10.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.